Stock Movers: Cidara Therapeutics Acquisition, Stubhub's Guidance Drop, Warner Bros. Discovery Auction

Cidara Therapeutics Acquisition

• 🚀 Cidara Therapeutics (CDTX) shares surged over 100% following Merck's agreement to acquire the company for $221.50 per share in cash, valuing the deal at approximately $9.2 billion.
• 💡 This acquisition is part of Merck's strategy to expand its treatment portfolio and offset anticipated sales erosion from patent expirations, notably for its blockbuster cancer drug Keytruda in 2028.
• 📈 Merck's move follows a previous acquisition of respiratory drug maker Verona for $10 billion, highlighting a trend of competitive deals within the pharmaceutical industry.

Stubhub's Guidance Uncertainty

• 📉 Stubhub shares dropped as much as 31% after the company, in its first quarterly report since going public in September, opted not to provide guidance for the current quarter.
• ⚠️ CEO Eric Baker cited the variable timing of ticket sales and difficulty in predicting consumer demand as reasons for the lack of short-term outlook, with a 2026 outlook planned for the fourth-quarter report.
• 📊 Analysts expressed surprise and added estimate uncertainty, with Bank of America downgrading the stock to neutral due to the lack of guidance.

Warner Brothers-Discovery Auction Process

• 📰 Warner Brothers-Discovery (WBD) shares rose up to 3% amid reports of an auction process for the company, with Paramount, Comcast, and Netflix reportedly preparing bids.
• ⏳ The initial deadline for non-binding bids is November 20th, and Warner Brothers aims to finalize a deal by the end of the year.
• 💼 While Paramount is reportedly interested in acquiring the entire company, Comcast and Netflix are focused on specific assets like the movie/TV studios and HBO Max, excluding cable networks.
• 🤝 Additionally, Warner Brothers Discovery amended CEO David Zaslav's contract to ensure his stock options remain eligible for vesting even if the company is sold, extending his employment term under certain conditions.